Altered systemic iron metabolism in Parkinson's disease

Neurology

Volumn 49, Issue 3, 1997, Pages 714-717

  Logroscino, G ^a,b,d   Marder, K ^a,b   Graziano, J ^b,c   Freyer, G ^c   Slavkovich, V ^c   LoIacono, N ^c   Cote, L ^a,b   Mayeux, Richard ^a,b,c  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d MIULLI GENERAL HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ARTICLE; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; IRON METABOLISM; LIPID PEROXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SUBSTANTIA NIGRA;

EID: 0030774367     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.714     Document Type: Article

References (26)

1. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
2. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
3. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
4. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995;92: 9603-9607.
5. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
6. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142: 820-827.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
8. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
9. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987:205-224.
10. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
11. Logroscino G, Marder K, Cote L, Tang M-X, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 1996;39:89-94.
12. Yeh Y-Y, Zee P. Micromethod for determining total iron-binding capacity by flameless atomic absorption spectrophotometry. Clin Chem 1974;20:360-364.
13. Miles L, Lipschitz D, Bieter CP, Cook JD. Measurements of serum ferritin by a 2-site immunoradiometric assay. Anal Chem 1974;61:209-224.
14. Greene R-J, Hall AD, Hider RC. The interaction of orally administered iron with levodopa and methyldopa therapy. J Pharm Pharmacol 1990;47:502-504.
15. Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989;45:220-225.
16. Campbell NRC, Rankine D, Goodridge AE, Hasinoff BB, Kara M. Sinemet-ferrous sulfate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990;30:599-605.
17. Stevens R, Jones Y, Micozzi M, Taylor P. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-1052.
18. Cabrera-Valdivia F, Jiménez-Jiménez FJ, Molina JA. et al. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci 1994;125:82-86.
19. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992;46:879-884.
20. Looker J, Sempos C, Liu K, Johnson C, Gunter E. Within person variance of biochemical indicators of iron status: effects on prevalence estimates. Am J Clin Nutr 1990;52:541-547.
21. Morris CM, Candy JM, Omar S, Bloxham CA, Edwardson JA. Transferrin receptors in the Parkinsonian midbrain. Neuropathol Appl Neurobiol 1994;20:468-472.
22. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993;72: 19-28.
23. Jaffrey SR, Haile DJ, Klausner RD, Harford JB. The interaction between the iron-responsive element binding protein and its cognate RNA is highly dependent upon both RNA sequence and structure. Nucleic Acids Res 1993;21:4627-4631.
24. Rouault TA, Stout CD, Kaptain S, Harford JB, Klausner RD. Structural relationship between iron-regulated RNA-binding protein (IRE-BP) and aconitase: functional implications. Cell 1991;64:881-883.
25. Kim H, Klausner R, Rouault T. Translational repressor activity is equivalent and is quantitatively predicted by in vitro RNA binding for two iron-responsive element binding proteins, IRP1 and IRP2. J Biol Chem 1995;270:4983-4986.
26. Hu J, Connor JR. Demonstration and characterization of the iron regulatory protein in human brain. J Neurochem 1996; 67:838-844.